Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

<h4>Background</h4>The TLR9 agonist CpG is increasingly applied in preclinical and clinical studies as a therapeutic modality to enhance tumor immunity. The clinical application of CpG appears, however, less successful than would be predicted from animal studies. One reason might be the...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Stefan Nierkens, Martijn H den Brok, Thijs Roelofsen, Jori A L Wagenaars, Carl G Figdor, Theo J Ruers, Gosse J Adema
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2009
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/9b71579ac2cc4de8ab648b64648303bf
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!